PMID- 26204906
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20181202
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 15
IP  - 8
DP  - 2015
TI  - Nintedanib in combination with docetaxel for second-line treatment of advanced 
      non-small-cell lung cancer.
PG  - 875-84
LID - 10.1586/14737140.2015.1069186 [doi]
AB  - Non-small lung cancer (NSCLC) is a lethal malignancy when diagnosed in advanced 
      stage. The evolution of chemotherapy and the development of agents targeting 
      certain molecular pathways involved in tumor progression improved the prognosis. 
      Nintedanib is a new tyrosine kinase inhibitor, which exerts its activity by 
      blocking VEGF, FGF and PDGF receptors and inhibits the angiogenic signaling by 
      preventing receptor dimerization. Several Phase I and II studies proved its 
      safety and efficacy in diverse solid tumors. In patients with advanced NSCLC, the 
      administration of nintedanib may offer an additional chemotherapy benefit in 
      terms of response rate, progression-free survival and overall survival 
      particularly in patients with adenocarcinoma histology, with manageable toxicity. 
      Here, we present an analytical review of literature regarding nintedanib and we 
      focus on its particular importance in NSCLC treatment.
FAU - Syrios, John
AU  - Syrios J
AD  - 2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, 171 Alexandras 
      Av., 11522, Athens, Greece.
FAU - Nintos, Georgios
AU  - Nintos G
FAU - Georgoulias, Vassilis
AU  - Georgoulias V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Indoles)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - G6HRD2P839 (nintedanib)
SB  - IM
MH  - Adenocarcinoma/drug therapy/pathology
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Docetaxel
MH  - Humans
MH  - Indoles/administration & dosage
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Molecular Targeted Therapy
MH  - Prognosis
MH  - Survival Rate
MH  - Taxoids/administration & dosage
OTO - NOTNLM
OT  - adenocarcinoma
OT  - angiogenesis
OT  - nintedanib
OT  - non-small-cell lung cancer
OT  - tyrosine kinase inhibitor
EDAT- 2015/07/25 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/07/25 06:00
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.1586/14737140.2015.1069186 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2015;15(8):875-84. doi: 
      10.1586/14737140.2015.1069186.